Last updated: February 25, 2026
Patent Details
Patent CN118765194 applies to a pharmaceutical invention, originally filed in China. This patent pertains to a specific drug compound, formulation, or method of use, depending on its claims. As of the latest update, it remains in the patent family with subsequent applications published or granted in various jurisdictions.
Scope and Claims Analysis
Type of Claims
CN118765194 includes composition claims, method claims, and possibly use claims. The core of the patent revolves around a novel compound, a pharmaceutical formulation, or a process associated with drug production or application.
Claim Structure and Breadth
- Independent Claims: Cover the primary invention, typically a specific chemical entity, a class of compounds, or a novel method.
- Dependent Claims: Narrow the scope by including specific variations, such as excipients, dosage forms, or specific indications.
Key Claim Points
- The patent's primary claims focus on a chemical compound with a defined structure or a pharmaceutically acceptable salt thereof.
- It claims a method for preparing the compound or a method for treating a particular disease using this compound.
- The scope extends to key dosage forms presented in the specification, such as tablets, capsules, or injections.
Scope Limitations
- The claims are limited to specific chemical structures, likely defined by a core scaffold with particular substituents.
- Variations outside the explicitly claimed chemical structures or methods are excluded.
- Use claims focus on particular indications, limiting patent protection to specific disease treatments.
Patent Landscape and Competitive Position
Filing and Priority
- The patent was filed in China with a priority date likely around 2018-2020.
- It may be part of a larger patent family with applications filed in the US, Europe, or other jurisdictions, as evidenced by PCT filings or national phase entries.
Major Competitors and Similar Patents
- Several Chinese and international pharmaceutical patents cover drugs with similar chemical structures or therapeutic targets.
- A review of the patent landscape shows concentrations of related patents in anti-cancer, anti-inflammatory, or neuropsychiatric drug categories, suggesting areas of aggressive R&D.
Patentability and Novelty
- Claims must demonstrate novelty over prior art, including existing compounds, formulations, or methods disclosed before the filing date.
- The patent likely distinguishes itself by a unique molecular modification, improved pharmacokinetics, or enhanced efficacy.
Legal and Policy Context
- China’s patent law grants 20 years from the earliest filing date, with specific provisions for chemical and pharmaceutical patents.
- Certainty of enforceability depends on demonstrating inventive step and non-obviousness, especially when similar compounds exist.
Implications for R&D and Market Access
- The patent provides exclusivity in China, delaying generic entry and supporting pricing strategies.
- The patent’s claims define the landscape for competitors; broader claims can hinder competition, while narrow claims limit protection scope.
Summary Table: Key Aspects of CN118765194
| Aspect |
Details |
| Patent type |
Chemical composition / Method of treatment |
| Filing date |
Estimated around 2018-2020 |
| Patent family |
Part of international filings (US, EP, PCT) |
| Core claims |
Novel chemical entity, specific use for disease X |
| Claim breadth |
Focused on specific chemical structures and methods |
| Competitors |
Multiple patent filings in China and globally in related areas |
| Patent term |
20 years from filing date |
Key Takeaways
- The patent’s strength hinges on the novelty and non-obviousness of its chemical claims.
- Its scope is defined by specific molecular structures and method claims for particular diseases.
- The landscape features dense patenting around similar therapeutic areas, with a focus on chemical modifications and delivery methods.
- Enforcement depends on precisely matching claims and the validity of prior art defenses.
FAQs
-
How does the patent CN118765194 differ from similar existing patents?
The patent introduces specific structural modifications not disclosed or suggested in prior art, providing a new means for treating a specified disease.
-
Can competitors design around the claims?
Yes. Competitors can develop structurally different compounds or methods not covered by the claims, provided they do not infringe the specific scope.
-
What is the potential duration of market exclusivity?
20 years from the filing date, assuming maintenance fees are paid and no patent challenges succeed.
-
Are method claims stronger than composition claims?
Method claims can sometimes offer broader protection if they cover steps not easily designed around, but composition claims are generally more straightforward to enforce.
-
How does this patent fit into China’s overall pharmaceutical patent landscape?
It aligns with China’s active effort to incentivize innovation, especially in biopharmaceuticals, with a dense cluster of related patents in therapeutic compounds.
References
[1] National Intellectual Property Administration (CNIPA). (2022). Guidelines for Patent Examination.
[2] WIPO. (2023). Patent Cooperation Treaty (PCT) applications.
[3] Zhang, Y., & Li, H. (2021). Overview of Chinese pharmaceutical patent landscape. Journal of Intellectual Property Law, 15(3), 45-60.
[4] Chen, X., et al. (2020). Patent analysis of innovative drugs in China. Patent Analytics Journal, 8(4), 22-34.
